Cangrelor is an intravenous, rapidly reversible P2Y12 adenosine diphosphate receptor antagonist that provides immediate, predictable platelet inhibition during percutaneous coronary intervention in patients not adequately pre-loaded with oral antiplatelet agents. Simson Pharma's Cangrelor reference standard and impurities support the precise potency control required of this parenteral antiplatelet.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cangrelor Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.